BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Jan. 6, 2026--
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its schedule for the publication of financial information for 2026.
|
Events
|
|
Dates*
|
|
2025 Full-Year Revenue
|
|
January 13, 2026
|
|
2025 Full-Year Results
|
|
February 24, 2026
|
|
2026 First-Quarter Revenue
|
|
April 14, 2026
|
|
Annual General Meeting
|
|
April 17, 2026
|
|
2026 First-Half Revenue
|
|
July 7, 2026
|
|
2026 First-Half Results
|
|
September 15, 2026
|
|
2026 Third-Quarter Revenue
|
|
October 13, 2026
|
|
|
|
|
(*) Subject to change. Press releases will be issued after market close.
|
Upcoming financial publication
-
2025 Full-Year Revenue, on January 13, 2026 after market
About IMPLANET
IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributes medical technology equipment. Its activities focus on an innovative solution to improve the treatment of spinal pathologies (JAZZ®), complemented by the product range of thoraco-lumbar screws, cages, and cervical plates, acquired through Orthopaedic & Spine Development (OSD) in May 2021. In 2022, the Company entered into a commercial, technological, and financial partnership with Sanyou Medical, China’s second-largest medical device manufacturer. As part of this strategic agreement, IMPLANET developed in 2024 the Jazz Spinal System™ hybrid fixation system, a unique new range featuring a comprehensive pedicle screw solution, combined with the market’s most advanced braided implant technology, JAZZ®. IMPLANET’s orthopedic platform is built on the traceability of its products. Protected by four families of international patents, JAZZ® has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA), CE marking in Europe, and ANVISA approval in Brazil. IMPLANET employs 46 people and generated €9.4 million in consolidated revenue in 2024. Based near Bordeaux, France, IMPLANET has operated a U.S. subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris.
For more information, visit www.Implanet.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260106586586/en/
IMPLANET
Ludovic Lastennet, CEO
David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55
investors@Implanet.com
NewCap
Investor Relations
Mathilde Bohin
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
NewCap
Media Relations
Arthur Rouillé
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
Source: IMPLANET
